• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 11, 2011

View Archived Issues

MS Drug's Therapeutic, Adverse Effects Separated in New Study

Gilenya (fingolimod, Novartis AG) which the FDA approved in 2010, has shaped the market, as the first oral drug for multiple sclerosis. (See BioWorld Today, Sept. 23, 2010.) Read More

Pain, Inflammation Specialist Orexo Seeks $40M in Offering

Shares in Orexo AB dipped 10 percent last week on news that the company was seeking SEK250 million (US$40.1 million) in a discounted rights offering directed at existing shareholders and convertible bond holders. Read More

Takeda Tempted by Fate; Adds to Regenerative Medicine Effort

Fate Therapeutics Inc.'s approach to stem cell therapy – developing small-molecule drugs aimed at modulating adult stem cells – has attracted another investor: Takeda Ventures Inc. Read More

Stock Movers

Read More

Clinic Roundup

Talon Therapeutics Inc., of San Mateo, Calif., began a Phase III trial of Marqibo (vincristine sulfate liposomes injection) for non-Hodgkin lymphoma. The study will be carried out by the German High-Grade non-Hodgkin lymphoma study group (DSHNHL). The trial will enroll 1,000 patients 61-80 years of age, and patient treatment will begin in the third quarter. Read More

Financings Roundup

PDL BioPharma Inc., of Incline Village, Nev., said it intends to offer $135 million worth of new convertible senior notes due May 2015. Underwriter BofA Merrill Lynch will have an option to purchase $20.25 million worth of additional notes to cover any overallotments. Read More

Earnings Roundup

Auxilium Pharmaceuticals Inc., of Malvern, Pa., reported first quarter net revenue of $58.4 million, a 28 percent increase over the first quarter of 2010 but still below analyst expectations of $61.1 million. First quarter revenues from Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture were $12.3 million and revenues from Testim (testosterone gel) for hypogonadism were $46.1 million. Read More

Other News To Note

Paladin Labs Inc., of Montreal, granted Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, an exclusive right to develop and commercialize fomepizole (marketed as Antizol in Canada and the U.S.) for the treatment of ethylene glycol and methanol poisonings in Japan. Read More

Allos Inks Ex-U.S. Folotyn Deal; $50M Up Front for PTCL Drug

Allos Therapeutics Inc. picked up $50 million in up-front cash in a much-anticipated ex-U.S. deal for peripheral T-cell lymphoma (PTCL) drug Folotyn (pralatrexate) and hopes the co-development and commercialization muscle of Mundipharma International Corp. Ltd. will help Folotyn capture a large portion of second-line PTCL market outside the U.S., estimated at about $400 million. Read More

Japanese Biopharmas Put Price Tag on Tsunami Damages

In the two months since the 9.0 Tohoku earthquake triggered a massive tsunami that ravaged much of Japan's eastern coast, several of the country's biopharmaceutical companies have worked around the clock to assess the damages and get their facilities back into production despite power outages and crippled infrastructure. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe